Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04272827
Other study ID # LIPLEG-3806
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 15, 2021
Est. completion date September 1, 2026

Study information

Verified date October 2023
Source Hautklinik Darmstadt
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether surgical treatment of lipedema (stage I, II or III) using liposuction significantly improves leg pain compared to the use of complex decongestive therapy (CDT).


Description:

After being informed about the study and potential risks, all patients that gave written informed consent will undergo a run-in phase of up to seven months for edema elimination and maintenance of results using complex decongestive therapy (CDT). Afterwards, patients will be assigned to one of the two treatment groups via internet randomization, provided that all inclusion and exclusion criteria continue to be met. Randomization will be 2:1 (intervention: control). In the intervention arm, patients will receive liposuction treatment (number of surgeries at the discretion of the treating study physician: a maximum of four surgical procedures, with a minimum of 5 and a maximum of 7 weeks between each surgery) with, if necessary, concomitant CDT to maintain the surgical results as required by the patient. The primary endpoint (regarding pain in the legs in stages I, II or III) will be assessed after an observation period of 12 months after final liposuction surgery. This is followed by a further follow-up period for 24 months to observe and document the further course.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 450
Est. completion date September 1, 2026
Est. primary completion date August 31, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Signed informed consent form 2. Female 3. Age = 18 years 4. Confirmed lipedema of the legs in stage I, II or III 5. Average pain in the legs for the last four weeks = 4 points on a numerical rating scale 6. Documentation of insufficient relief of symptoms by conservative measures 7. Willingness and ability to perform conservative measures according to the study protocol, during and, if necessary, after liposuction treatment 8. Full legal capacity Exclusion Criteria: 1. Concurrent lipedema of the arms and legs, in which co-occurrence of lipedema in the arms affects the primary endpoint (i.e., average leg pain), at the discretion of the study investigator 2. Previous liposuctions 3. Diseases that may limit operability at the discretion of the study physician, e.g. cardiac diseases, coagulation disorders, metabolic diseases, infectious diseases (active), epilepsy; diseases requiring immunosuppression or anticoagulation with medication; allergies to medication accompanying surgery 4. Weight >120.0 kg 5. Medical conditions that affect adequate complex decongestive therapy (CDT) at the discretion of the study physician, e.g. heart failure (volume stress), lack of physical ability to wear compression stockings (e.g. joint disease, neurological deficits). 6. Primary obesity without disproportion and without evidence of lipedema 7. Secondary obesity 8. Fat distribution disorders of other genesis (e.g. painless lipohypertrophy, benign symmetric lipomatoses or lipomatosis dolorosa) 9. Other edema-causing diseases (such as lymphedema, phlebedema, or myxedema) 10. Lack of willingness to ensure adequate contraception 11. Positive pregnancy test 12. Breastfeeding 13. Use of a lymphomat 14. Participation in other clinical studies 15. Purely cosmetic reasons for participation in the study

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Liposuction
Liposuction treatment will be performed according to the study protocol using the "wet technique" depending on the amount of fat to be removed, if necessary in several sessions.

Locations

Country Name City State
Germany Hautmedizin Bad Soden Bad Soden am Taunus Hessen
Germany Johanniter GmbH Waldkrankenhaus Bonn Bonn North Rhine-Westphalia
Germany Klinik und Praxisklinik für Plastische Chirurgie Cologne North Rhine-Westphalia
Germany MVZ Praxis Cologne North Rhine-Westphalia
Germany Hautklinik Darmstadt Darmstadt Hessen
Germany MVZ Praxis Dr. Cornely Düsseldorf MVZ Corius Nordrhein GmbH Düsseldorf NRW
Germany Praxis für Dermatologie, Dermatochirurgie und Phlebologie Freiburg Baden-Württemberg
Germany Venenzentrum Freiburg Freiburg Baden-Württemberg
Germany Hautarztpraxis Mühltal Mühltal Hessen
Germany Evangelisches Krankenhaus Oldenburg Klinik für Plastische, Ästhetische, Rekonstruktive und Handchirurgie Oldenburg Lower Saxony
Germany Klinikum Ernst von Bergmann Potsdam Brandenburg
Germany Universitätsklinikum Regensburg Regensburg Bavaria

Sponsors (2)

Lead Sponsor Collaborator
Hautklinik Darmstadt The Clinical Trials Centre Cologne

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Successful Pain Reduction After 12 Months (= 2 Points on a Numeric Rating Scale) The primary end point is the relevant reduction of the average pain of the last four weeks in the legs (= 2 points on a Numeric Rating Scale; German Pain Questionnaire) 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation. 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Change in Pain Severity as Assessed by German Pain Questionnaire Change in severity according to von Korff et al. (1992) regarding pain in the legs (stage I, II or III). The severity is calculated based on the questions of the German Pain Questionnaire according to von Korff et al (1992). The assessment of the pain intensity as well as the impairment and information on the days of impairment are included in the calculation of the severity (classes 0 = no pain to 4 = high, pain-related impairment, strongly limiting). 12 months after completed liposuction treatment (intervention group) or after randomization (control group) compared with the time of randomisation)
Secondary Change in Health-Related Quality of Life According to SF-36 Questionnaire Change in health-related quality of life according to SF-36 questionnaire. 12 months after completed liposuction treatment (intervention group) or after randomization (control group) compared with the time of randomisation)
Secondary Change in Health-Related Quality of Life According to DLQI Questionnaire Change in health-related quality of life according to DLQI questionnaire (a clinically relevant change corresponds to = 4 points change in DLQI sum score). 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Change in Health-Related Quality of Life According to WHOQOL-BREF Questionnaire Change in health-related quality of life according to WHOQOL-BREF questionnaire. 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Change in Total Impairment According to Schmeller et al. (2010) Total impairment is measured by taking the mean of 7 numerical rating scales assessing the domains pain (spontaneous, pressure), swelling, hematoma, movement, cosmetic appearance and quality of life (0 (none) - 10 (always/very strong) points), see Schmeller et al. (2010). 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Altered Depression Tendency According to PHQ-9 Questionnaire Altered depression tendency according to PHQ-9 questionnaire (a clinically relevant improvement corresponds to = 5 points reduction in PHQ-9 sum score). 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Altered Hematoma Tendency According to Schmeller et al. (2010) Hematoma ("Are you prone to bruising?") is measured by a numerical rating scale (0 (none) - 10 (always/very strong) points), see Schmeller et al. (2010). 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Changed Prevalence of Edema Changed prevalence of edema 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Change in the Scope of the Physical Therapy The scope of the physical therapy is measured by the number of treatment sessions per month. 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Change in Body Fat Percentage According to Wright et al. (1981) Change in body fat percentage, determined according to formula from Wright et al. (1981), collected by means of measuring tape at the following points:
abdominal circumference: measurement at the level of the navel. The tape measure is placed horizontally around the body
neck circumference: measurement below the larynx
body size
hip circumference: the widest part of the hip is measured.
12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Change of Leg Circumference by Means of Measuring Tape Change of leg circumference of the left and right leg by means of measuring tape at five specified measuring points:
lower leg cuffs
calf center
knee
10 cm below the groin
hips (iliac crest).
12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Movement Restriction Reduction According to LEFS Sum Score Relevant reduction in movement restriction (stage I, II, or III; = 9 points improvement in LEFS sum score) 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Number of Recurrent Interventions Number of recurrent interventions 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Number of (Serious) Adverse Events Number of (serious) adverse events 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Number of Therapy Interruptions Caused by Adverse Events Discontinuation of therapy caused by adverse events 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
Secondary Optional: Change of the Leg Volume by Means of Perometry Optional: Change of the leg volume of the left and right leg (e.g. by means of perometry etc.) 12 months after completed liposuction treatment (intervention group) or after randomisation (control group) compared with the time of randomisation)
See also
  Status Clinical Trial Phase
Completed NCT04492046 - Complex Decongestive Applications in Patients With Lipedema
Completed NCT04643392 - Physiotherapy Applications in Upper Extremity Lipedema
Recruiting NCT05464927 - Visualizing Vascular Mechanisms of Lipedema
Completed NCT02907411 - Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS) N/A
Completed NCT06238791 - Plantar Pressure Analysis and Foot Biomechanics in Lipedema and Chronic Venous Disease
Completed NCT03710798 - Effect of an Low Carbon High Fat Diet on Pain- and Quality of Life in Patients With Lipedema N/A
Completed NCT03758651 - Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study
Not yet recruiting NCT04166084 - Trunk Stabilization Exercises at Lipoedema Patients N/A
Recruiting NCT05628948 - Vascular Lab Resource (VLR) Biorepository
Not yet recruiting NCT05944796 - Diathermy Effectiveness in Reducing Subcutaneous Adipose Tissue Affected by Lipedema N/A
Completed NCT05616962 - Collected Data of Medical Food, Vasculera or Diosmiplex, in Clinic Patients 20 to 70 Years Old Diagnosed With Lipedema N/A
Active, not recruiting NCT04632810 - Effect of Ketosis on Pain and Quality of Life in Patients With Lipedema N/A
Recruiting NCT05284266 - The National Lipedema Study N/A
Active, not recruiting NCT06338059 - Relationship Between Vitamin D and Vitamin B12 Levels and Neuropathic Pain in Lipedema
Completed NCT04076891 - Treatment of Women With Lipedema Involving Substantial Fat Above the Knee or of Women and Men With Nodular Dercum's Disease Phase 2
Completed NCT03492840 - Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease Phase 2
Recruiting NCT02838277 - Insight Into Subcutaneous Adipose Tissue Disorders N/A
Completed NCT05966779 - Physical Therapy in Lipedema Surgery
Completed NCT05488977 - The Effects of Endurance Training on Lipedema N/A
Completed NCT04213989 - Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling) N/A